zifeng-ai/TrialReviewBench huggingface dataset:
Study: Masterson TA
Number of patients: 100
Whole gland salvage (%): 100.0
Toxicity scoring criteria: Descriptive
Study: Strope SA
Number of patients: 6
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Pre-salvage PSA (ng/ml): 9.3
Follow-up (months): 15.0
Toxicity scoring criteria: EPIC
Study: Eandi JA
Number of patients: 18
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 67.0
Pre-salvage PSA (ng/ml): 6.8
Per-salvage ADT use (%): 22.2
Interval from initial treatment to recurrence or salvage (%): 79.0
Follow-up (months): 18.0
Toxicity scoring criteria: Descriptive
Study: Dall'Oglio MF
Number of patients: 9
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 59.0
Per-salvage ADT use (%): 44.4
Interval from initial treatment to recurrence or salvage (%): 36.0
Follow-up (months): 30.0
Toxicity scoring criteria: Descriptive
Study: Sanderson KM
Number of patients: 51
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 65.0
Pre-salvage PSA (ng/ml): 8.0
Per-salvage ADT use (%): 55.0
Interval from initial treatment to recurrence or salvage (%): 62.4
Follow-up (months): 86.4
Toxicity scoring criteria: Descriptive
Study: Bianco FJ Jr
Number of patients: 100
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 65.0
Pre-salvage PSA (ng/ml): 5.9
Interval from initial treatment to recurrence or salvage (%): 48.0
Follow-up (months): 60.0
Study: Kim SP
Number of patients: 7
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 68.0
Interval from initial treatment to recurrence or salvage (%): 38.6
Follow-up (months): 3.0
Toxicity scoring criteria: Descriptive
Study: Brenner PC
Number of patients: 10
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 60.0
Pre-salvage PSA (ng/ml): 19.0
Per-salvage ADT use (%): 50.0
Interval from initial treatment to recurrence or salvage (%): 77.0
Follow-up (months): 35.0
Toxicity scoring criteria: Descriptive
Study: Rogers E
Number of patients: 40
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 61.5
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 58.9
Follow-up (months): 39.0
Toxicity scoring criteria: Descriptive
Study: Boris RS
Number of patients: 11
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 64.9
Pre-salvage PSA (ng/ml): 5.2
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 53.2
Follow-up (months): 20.5
Toxicity scoring criteria: IPSS
Study: Mador DR
Number of patients: 7
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 62.0
Per-salvage ADT use (%): 42.9
Interval from initial treatment to recurrence or salvage (%): 24.0
Toxicity scoring criteria: Descriptive
Study: Stein A
Number of patients: 13
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 64.3
Per-salvage ADT use (%): 1.0
Interval from initial treatment to recurrence or salvage (%): 65.4
Toxicity scoring criteria: Descriptive
Study: Neerhut GJ
Number of patients: 16
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 66.6
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 39.4
Follow-up (months): 20.0
Toxicity scoring criteria: Descriptive
Study: Leonardo C
Number of patients: 32
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 63.0
Pre-salvage PSA (ng/ml): 2.3
Per-salvage ADT use (%): 15.6
Interval from initial treatment to recurrence or salvage (%): 31.0
Follow-up (months): 35.0
Toxicity scoring criteria: Descriptive
Study: Cheng L
Number of patients: 86
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 66.0
Per-salvage ADT use (%): 55.8
Interval from initial treatment to recurrence or salvage (%): 30.0
Follow-up (months): 69.6
Study: Tefilli MV
Number of patients: 27
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Pre-salvage PSA (ng/ml): 9.1
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 39.5
Follow-up (months): 34.3
Toxicity scoring criteria: Descriptive
Study: Zugor V
Number of patients: 13
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 63.1
Pre-salvage PSA (ng/ml): 14.4
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 48.9
Follow-up (months): 22.8
Toxicity scoring criteria: Descriptive
Study: Ward JF
Number of patients: 138
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 65.1
Pre-salvage PSA (ng/ml): 8.9
Per-salvage ADT use (%): 32.0
Interval from initial treatment to recurrence or salvage (%): 40.2
Follow-up (months): 92.4
Toxicity scoring criteria: Descriptive
Study: Garzotto M
Number of patients: 29
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 66.0
Pre-salvage PSA (ng/ml): 11.8
Per-salvage ADT use (%): 82.7
Interval from initial treatment to recurrence or salvage (%): 58.8
Follow-up (months): 61.2
Toxicity scoring criteria: Descriptive
Study: Metcalfe MJ
Number of patients: 70
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Pre-salvage PSA (ng/ml): 3.4
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 69.1
Follow-up (months): 33.6
Study: Kenney PA
Number of patients: 20
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 66.0
Pre-salvage PSA (ng/ml): 2.5
Per-salvage ADT use (%): 40.0
Follow-up (months): 16.8
Toxicity scoring criteria: Clavien
Study: Kenney PA
Number of patients: 19
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 66.0
Pre-salvage PSA (ng/ml): 4.5
Per-salvage ADT use (%): 21.1
Follow-up (months): 16.8
Toxicity scoring criteria: Clavien
Study: Nuñez-Mora C
Number of patients: 9
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 59.3
Pre-salvage PSA (ng/ml): 9.1
Per-salvage ADT use (%): 11.1
Interval from initial treatment to recurrence or salvage (%): 42.7
Follow-up (months): 26.8
Toxicity scoring criteria: Descriptive
Study: Vaidya A
Number of patients: 6
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 64.4
Per-salvage ADT use (%): 66.7
Interval from initial treatment to recurrence or salvage (%): 36.0
Follow-up (months): 27.0
Toxicity scoring criteria: Descriptive
Study: Mohler JL
Number of patients: 41
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 64.0
Pre-salvage PSA (ng/ml): 4.1
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 64.0
Follow-up (months): 91.0
Toxicity scoring criteria: Descriptive
Study: Gontero P
Number of patients: 395
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 95.2
Age (years): 66.3
Pre-salvage PSA (ng/ml): 6.6
Per-salvage ADT use (%): 5.1
Interval from initial treatment to recurrence or salvage (%): 63.6
Follow-up (months): 36.0
Toxicity scoring criteria: Descriptive
Study: Darras J
Number of patients: 11
Whole gland salvage (%): 100.0
Age (years): 60.5
Pre-salvage PSA (ng/ml): 3.7
Per-salvage ADT use (%): 27.3
Interval from initial treatment to recurrence or salvage (%): 36.9
Follow-up (months): 63.0
Toxicity scoring criteria: Descriptive
Study: Ogaya-Pinies G
Number of patients: 68
Whole gland salvage (%): 100.0
Age (years): 65.8
Pre-salvage PSA (ng/ml): 4.0
Per-salvage ADT use (%): 27.3
Interval from initial treatment to recurrence or salvage (%): 81.5
Follow-up (months): 14.0
Toxicity scoring criteria: Descriptive
Study: Chade DC
Number of patients: 404
Whole gland salvage (%): 100.0
Age (years): 65.0
Pre-salvage PSA (ng/ml): 4.5
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 41.0
Follow-up (months): 52.8
Study: Bonet X
Number of patients: 63
Whole gland salvage (%): 100.0
Age (years): 65.6
Pre-salvage PSA (ng/ml): 4.5
Interval from initial treatment to recurrence or salvage (%): 63.2
Follow-up (months): 22.5
Toxicity scoring criteria: Descriptive
Study: Heidenreich A
Number of patients: 55
Whole gland salvage (%): 100.0
Age (years): 65.3
Pre-salvage PSA (ng/ml): 7.8
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 32.0
Follow-up (months): 23.0
Toxicity scoring criteria: Descriptive
Study: Clery R
Number of patients: 40
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 64.0
Pre-salvage PSA (ng/ml): 5.0
Per-salvage ADT use (%): 14.0
Interval from initial treatment to recurrence or salvage (%): 13.0
Follow-up (months): 24.0
Toxicity scoring criteria: Descriptive
Study: Moul JW
Number of patients: 12
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Interval from initial treatment to recurrence or salvage (%): 32.0
Follow-up (months): 32.0
Toxicity scoring criteria: Descriptive
Study: Vallancien G
Number of patients: 7
Whole gland salvage (%): 100.0
Age (years): 66.2
Per-salvage ADT use (%): 42.9
Interval from initial treatment to recurrence or salvage (%): 57.4
Follow-up (months): 11.2
Toxicity scoring criteria: Descriptive
Study: Orré M
Number of patients: 7
Whole gland salvage (%): 100.0
Age (years): 66.0
Pre-salvage PSA (ng/ml): 6.6
Per-salvage ADT use (%): 57.1
Interval from initial treatment to recurrence or salvage (%): 46.0
Follow-up (months): 24.0
Toxicity scoring criteria: Descriptive
Study: Yuh B
Number of patients: 51
Whole gland salvage (%): 100.0
Age (years): 68.0
Per-salvage ADT use (%): 19.6
Interval from initial treatment to recurrence or salvage (%): 68.0
Follow-up (months): 36.0
Toxicity scoring criteria: Descriptive
Study: Paparel P
Number of patients: 149
Whole gland salvage (%): 100.0
Age (years): 65.0
Pre-salvage PSA (ng/ml): 5.1
Interval from initial treatment to recurrence or salvage (%): 58.8
Follow-up (months): 55.2
Toxicity scoring criteria: Descriptive
Study: Mbeutcha A
Number of patients: 10
Whole gland salvage (%): 100.0
Age (years): 69.0
Pre-salvage PSA (ng/ml): 4.4
Per-salvage ADT use (%): 20.0
Interval from initial treatment to recurrence or salvage (%): 86.5
Follow-up (months): 22.5
Toxicity scoring criteria: CTCAE
Study: Yamada Y
Number of patients: 42
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 72.0
Pre-salvage PSA (ng/ml): 3.5
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 73.0
Follow-up (months): 36.0
Toxicity scoring criteria: CTCAE
Study: Chen CP
Number of patients: 52
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 67.5
Pre-salvage PSA (ng/ml): 9.3
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 51.6
Follow-up (months): 59.6
Toxicity scoring criteria: CTCAE
Study: Gawkowska-Suwinska M
Number of patients: 15
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 67.0
Pre-salvage PSA (ng/ml): 4.0
Per-salvage ADT use (%): 26.7
Interval from initial treatment to recurrence or salvage (%): 54.0
Follow-up (months): 9.0
Toxicity scoring criteria: RTOG, EORTC
Study: Wojcieszek P
Number of patients: 83
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 70.0
Pre-salvage PSA (ng/ml): 3.1
Per-salvage ADT use (%): 53.0
Interval from initial treatment to recurrence or salvage (%): 67.0
Follow-up (months): 41.0
Toxicity scoring criteria: CTCAE
Study: Kukiełka AM
Number of patients: 25
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 71.0
Pre-salvage PSA (ng/ml): 2.8
Per-salvage ADT use (%): 40.0
Interval from initial treatment to recurrence or salvage (%): 43.0
Follow-up (months): 13.0
Toxicity scoring criteria: CTCAE
Study: Tharp M
Number of patients: 7
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 71.0
Pre-salvage PSA (ng/ml): 5.5
Per-salvage ADT use (%): 100.0
Interval from initial treatment to recurrence or salvage (%): 55.0
Follow-up (months): 58.0
Toxicity scoring criteria: CTCAE
Study: Lee B
Number of patients: 21
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 68.0
Pre-salvage PSA (ng/ml): 5.9
Per-salvage ADT use (%): 52.4
Interval from initial treatment to recurrence or salvage (%): 63.6
Follow-up (months): 18.7
Toxicity scoring criteria: CTCAE
Study: Henríquez López
Number of patients: 75
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Pre-salvage PSA (ng/ml): 4.1
Per-salvage ADT use (%): 29.0
Follow-up (months): 52.0
Toxicity scoring criteria: CTCAE
Study: Kollmeier MA
Number of patients: 61
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 74.0
Pre-salvage PSA (ng/ml): 3.9
Per-salvage ADT use (%): 44.2
Interval from initial treatment to recurrence or salvage (%): 67.2
Follow-up (months): 31.0
Toxicity scoring criteria: CTCAE
Study: Baumann BC
Number of patients: 8
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 75.0
Pre-salvage PSA (ng/ml): 5.0
Per-salvage ADT use (%): 100.0
Interval from initial treatment to recurrence or salvage (%): 56.1
Follow-up (months): 61.0
Toxicity scoring criteria: CTCAE
Study: Łyczek J
Number of patients: 115
Age (years): 70.0
Per-salvage ADT use (%): 100.0
Interval from initial treatment to recurrence or salvage (%): 49.5
Toxicity scoring criteria: RTOG, EORTC
Study: Murgic J
Number of patients: 15
Whole gland salvage (%): 0.0
Biopsy-proven occurrence (%): 100.0
Age (years): 75.0
Pre-salvage PSA (ng/ml): 4.1
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 91.2
Follow-up (months): 36.0
Toxicity scoring criteria: CTCAE
Study: Maenhout M
Number of patients: 17
Whole gland salvage (%): 0.0
Biopsy-proven occurrence (%): 100.0
Age (years): 69.0
Pre-salvage PSA (ng/ml): 4.8
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 96.0
Follow-up (months): 10.0
Toxicity scoring criteria: CTCAE
Study: Jiang P
Number of patients: 29
Whole gland salvage (%): 0.0
Biopsy-proven occurrence (%): 0.0
Age (years): 75.5
Pre-salvage PSA (ng/ml): 4.1
Per-salvage ADT use (%): 13.8
Interval from initial treatment to recurrence or salvage (%): 66.0
Follow-up (months): 73.0
Toxicity scoring criteria: CTCAE
Study: Jo Y
Number of patients: 11
Whole gland salvage (%): 0.0
Biopsy-proven occurrence (%): 100.0
Age (years): 66.0
Pre-salvage PSA (ng/ml): 5.8
Per-salvage ADT use (%): 0.0
Interval from initial treatment to recurrence or salvage (%): 36.0
Follow-up (months): 29.0
Toxicity scoring criteria: CTCAE
Study: Fuller DB
Number of patients: 50
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 100.0
Age (years): 74.0
Pre-salvage PSA (ng/ml): 4.0
Per-salvage ADT use (%): 14.0
Interval from initial treatment to recurrence or salvage (%): 98.0
Follow-up (months): 44.0
Toxicity scoring criteria: CTCAE
Study: Vavassori A
Number of patients: 6
Whole gland salvage (%): 100.0
Biopsy-proven occurrence (%): 0.0
Age (years): 68.0
Pre-salvage PSA (ng/ml): 3.7
Per-salvage ADT use (%): 66.7
Follow-up (months): 11.3
Toxicity scoring criteria: EORTC, RTOG
Study: Leroy T
Number of patients: 23
Whole gland salvage (%): 82.6
Biopsy-proven occurrence (%): 83.0
Age (years): 70.0
Pre-salvage PSA (ng/ml): 2.5
Per-salvage ADT use (%): 60.8
Interval from initial treatment to recurrence or salvage (%): 65.0
Follow-up (months): 22.0
Toxicity scoring criteria: CTCAE
Study: Miszczyk L
Number of patients: 38
Whole gland salvage (%): 89.5
Biopsy-proven occurrence (%): 68.4
Age (years): 71.6
Pre-salvage PSA (ng/ml): 4.3
Per-salvage ADT use (%): 55.3
Interval from initial treatment to recurrence or salvage (%): 101.0
Follow-up (months): 14.4
Toxicity scoring criteria: EORTC, RTOG
Study: Pasquier D
Number of patients: 100
Whole gland salvage (%): 49.0
Biopsy-proven occurrence (%): 100.0
Age (years): 71.2
Pre-salvage PSA (ng/ml): 4.3
Per-salvage ADT use (%): 34.0
Interval from initial treatment to recurrence or salvage (%): 90.0
Follow-up (months): 29.3
Toxicity scoring criteria: CTCAE
Study: Mbeutcha A
Number of patients: 18
Whole gland salvage (%): 0.0
Age (years): 69.0
Pre-salvage PSA (ng/ml): 4.5
Per-salvage ADT use (%): 55.6
Interval from initial treatment to recurrence or salvage (%): 77.0
Follow-up (months): 14.5
Toxicity scoring criteria: CTCAE
Study: Janoray G
Number of patients: 11
Whole gland salvage (%): 0.0
Biopsy-proven occurrence (%): 0.0
Age (years): 80.0
Pre-salvage PSA (ng/ml): 3.4
Per-salvage ADT use (%): 9.0
Interval from initial treatment to recurrence or salvage (%): 98.4
Follow-up (months): 11.7
Toxicity scoring criteria: CTCAE, IPSS
Study: Jereczek-Fossa BA
Number of patients: 15
Whole gland salvage (%): 0.0
Biopsy-proven occurrence (%): 10.0
Age (years): 68.8
Pre-salvage PSA (ng/ml): 3.5
Per-salvage ADT use (%): 33.0
Interval from initial treatment to recurrence or salvage (%): 66.0
Follow-up (months): 9.5
Toxicity scoring criteria: EORTC, RTOG